CAR T-cell therapy for stomach and esophagus cancer
Part of Cancer, Digestive system, Hormones & metabolism, Skin clinical trials.
This trial tests a new treatment called CAR T-cell therapy that targets a protein called mesothelin found on some cancer cells. It is for people with advanced or recurrent cancer of the stomach or esophagus that has spread or come back after prior treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have a confirmed diagnosis of stomach or esophagus adenocarcinoma that has spread or returned.
- You must be in fairly good health (able to do daily activities without help).
- You must have tried at least one prior treatment that did not work or caused side effects.
- You must have a tumor that shows mesothelin on a lab test.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
This study tests a new treatment called CAR T cells that target a protein called mesothelin found on certain cancer cells. The CAR T cells are made from your own immune cells and may help shrink tumors that have not responded to other therapies.
This early-phase study tests a lab-made immune cell therapy (CAR T cells) that targets a protein called mesothelin (MSLN) in advanced or metastatic solid cancers. It may help your body better recognize and attack tumor cells, especially if standard first treatments did not work or are not available.
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
This Phase 1 trial tests a lab-made immune therapy (anti-mesothelin CAR-T) for adults with solid tumors that have come back or did not respond to standard treatment. It targets cancers that are mesothelin-positive in tumor testing and aims to see if the treatment is safe and can work.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
Hear when a new Esophageal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.